» Articles » PMID: 17245566

Evaluation of an Inflammation-based Prognostic Score (GPS) in Patients Undergoing Resection for Colon and Rectal Cancer

Overview
Date 2007 Jan 25
PMID 17245566
Citations 223
Authors
Affiliations
Soon will be listed here.
Abstract

Background/aims: The aim of the study was to examine the value of the combination of an elevated C-reactive protein and hypoalbuminaemia (GPS) in predicting cancer-specific survival after resection for colon and rectal cancer.

Materials And Methods: The GPS was constructed as follows: Patients with both an elevated C-reactive protein (>10 mg/l) and hypoalbuminaemia (<35 g/l) were allocated a score of 2. Patients in whom only one or none of these biochemical abnormalities was present were allocated a score of 1 or 0, respectively.

Results: A GPS of 1 (n = 109) was mainly due to an elevated C-reactive protein concentration and the remainder due to hypoalbuminaemia. In those patients with a GPS of 1 due to hypoalbuminaemia (n = 16), the 3-year overall survival rate was 94% compared with 62% in those patients with a GPS of 1 due to an elevated C-reactive protein concentration (n = 93, p = 0.0094). Therefore, the GPS was modified such that patients with hypoalbuminaemia were assigned a score of 0 in the absence of an elevated C-reactive protein. On univariate analysis of those patients with colon and rectal cancer, the modified GPS (p < 0.0001) was significantly associated with overall and cancer specific survival. On univariate survival analysis of those patients with Dukes B colon and rectal cancer, the modified GPS (p < 0.01) was significantly associated with overall and cancer specific survival.

Conclusion: The results of the present study indicate that the GPS, before surgery, predicts overall and cancer-specific survival after resection of colon and rectal cancer.

Citing Articles

Novel Preoperative Immune Prognostic Index for Predicting Outcomes in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma.

Shibata K, Iwatani K, Imai Y, Yoshihara K, Miyajima K, Fukuokaya W In Vivo. 2025; 39(2):824-833.

PMID: 40010955 PMC: 11884453. DOI: 10.21873/invivo.13885.


Immune-nutritional indicators predict short-term mortality in older patients after emergency gastrointestinal surgery: a retrospective study.

Jin Z, Yang T, Wang Z BMC Gastroenterol. 2025; 25(1):99.

PMID: 39984877 PMC: 11844028. DOI: 10.1186/s12876-024-03583-3.


Prognostic value of Glasgow prognostic score in hematological malignancies: a systematic review and meta-analysis.

Jiang L, Jin W Int J Hematol. 2025; .

PMID: 39899232 DOI: 10.1007/s12185-025-03935-z.


Optimising (re-)irradiation for locally recurrent head and neck cancer: impact of dose-escalation, salvage surgery, PEG tube and biomarkers on oncological outcomes-a single centre analysis.

Schleifenbaum J, Morgenthaler J, Sharma S, Klussmann J, Linde P, Wegen S Radiat Oncol. 2025; 20(1):1.

PMID: 39748422 PMC: 11697932. DOI: 10.1186/s13014-024-02570-y.


The prognostic impact of C-reactive protein and albumin in patients diagnosed with acute myeloid leukaemia.

Skar E, Wendelbo O, Reikvam H EJHaem. 2024; 5(6):1223-1235.

PMID: 39691271 PMC: 11647729. DOI: 10.1002/jha2.1022.


References
1.
Kritchevsky S, Cesari M, Pahor M . Inflammatory markers and cardiovascular health in older adults. Cardiovasc Res. 2005; 66(2):265-75. DOI: 10.1016/j.cardiores.2004.12.026. View

2.
Graziano F, Cascinu S . Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough?. Ann Oncol. 2003; 14(7):1026-38. DOI: 10.1093/annonc/mdg284. View

3.
Murri A, Bartlett J, Canney P, Doughty J, Wilson C, McMillan D . Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 2006; 94(2):227-30. PMC: 2361117. DOI: 10.1038/sj.bjc.6602922. View

4.
Glen P, Jamieson N, McMillan D, Carter R, Imrie C, McKay C . Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology. 2006; 6(5):450-3. DOI: 10.1159/000094562. View

5.
Nielsen H, Christensen I, Sorensen S, Moesgaard F, Brunner N . Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol. 2000; 7(8):617-23. DOI: 10.1007/BF02725342. View